Botulinum toxin a evidence for Masseter hypertrophy / jaw reduction

Abstract summary (English) BACKGROUND: Postoperative pain management due to muscular tension and spasm following mandibular advancement surgery can be clinically challenging. Botulinum toxin type A (BoNT-A) has demonstrated analgesic and muscle-relaxant properties in various medical applications, but its role in acute postoperative pain control in orthognathic procedures remains unclear. PURPOSE: The purpose of this study was to evaluate...

Journal Article, Randomized Controlled Trial

Abstract summary (English) BACKGROUND: Masseter muscle prominence (MMP) may be aesthetically bothersome to some individuals, leading them to seek treatment for a slimmer lower face. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of MMP, including patient-reported outcomes (PROs). METHODS: This was a prospective, multicenter trial including a randomized, double-blind,...

Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase III

Abstract summary (English) BACKGROUND: Botulinum toxin type A (BoNT-A) is commonly used in neuromuscular disorders and cosmetic fields, but the detailed histological and subcellular changes in masticatory muscles, mainly in masseter, remain underexplored. METHODS: The literature review was conducted using the PubMed and Cochrane databases between January 2000 and September 2024. Studies of BoNT-A injection in masseters with available full-...

Journal Article, Systematic Review, Review

Abstract summary (English) BACKGROUND: Masseter muscle prominence (MMP) contributes to a widened lower facial shape, considered aesthetically undesirable to some individuals. This study assessed lower facial shaping improvements with onabotulinumtoxinA. METHODS: In a phase 2, randomized, placebo-controlled study, onabotulinumtoxinA (24, 48, 72, or 96 U) or placebo was injected intramuscularly (3 sites per masseter) into subjects with...

Journal Article, Clinical Trial, Phase II, Randomized Controlled Trial

Abstract summary (English) BACKGROUND: Botulinum neurotoxins are used to treat masseter muscle prominence (MMP), benign bilateral masseter muscle enlargement which can be aesthetically undesirable. Limited data report botulinum neurotoxin injections in the muscles of mastication, with subsequent reduction in biomechanical loading, may impact mandibular bone density. OBJECTIVES: This study evaluates whether changes in mandibular bone density...

Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II

Abstract summary (English) BACKGROUND: Bruxism can cause masseter hypertrophy, discomfort, and facial asymmetry. Occlusal splints are widely used to manage pain and improve mandibular function, while botulinum toxin A (BTX-A) has gained interest for directly reducing masseter muscle thickness. However, the comparative effectiveness of these treatments remains unclear.

Journal Article, Randomized Controlled Trial, Comparative Study

Abstract summary (English) UNLABELLED: The aim of this Randomized Controlled Trial (RCT) was to evaluate the pain relief and mouth opening achieved with preoperative injection of Botulinum Toxin-A (BTX-A) into bilateral temporalis and masseter muscles in patients with Oral Submucous Fibrosis (OSMF), following surgical intervention, compared to the control group. Additionally, the effectiveness of BTX-A in the uptake of the Buccal Fat Pad...

Journal Article, Randomized Controlled Trial

Abstract summary (English) INTRODUCTION: Bruxism is a common problem defined by the involuntary grinding or clenching of teeth. This study aimed to compare the treatment outcomes of Botulinum toxin type A (BTX/A) injections into the masseter and lateral pterygoid muscles with injections into the masseter muscle only in patients with bruxism. MATERIALS AND METHODS: Thirty patients with bruxism aged 18-45 years were randomly divided into two...

Journal Article, Randomized Controlled Trial, Comparative Study, Research Support, Non-U.S. Gov't

Abstract summary (English) BACKGROUND: Masseter muscle prominence (MMP) is a benign condition characterized by a wide, square, or trapezoidal lower facial shape, which may be considered undesirable. OBJECTIVES: To evaluate onabotulinumtoxinA (onabotA) efficacy and safety for MMP treatment. METHODS: In a Phase 2b study, adults with investigator- and participant-assessed bilateral Grade 4/5 MMP on the 5-grade MMP Scale (MMPS) and...

Journal Article, Clinical Trial, Phase II, Randomized Controlled Trial, Multicenter Study

Abstract summary (English) This overview aimed at assessing botulinum toxin type A (BoNT-A)'s effectiveness in managing bruxism compared to a placebo, the absence of treatment, or other interventions in adults. Only systematic reviews (SRs), with or without a meta-analysis, were included. A comprehensive literature search was conducted on 16 June 2024, encompassing seven databases and grey literature sources.

Journal Article, Systematic Review